Reconvalescent blood products, Passive vaccine
32243945 ä. Treatment With Convalescent Plasma for Critically Ill Patients With SARS-CoV-2 Infection
32375025 ä. Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies
32344202 2020. Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development
32298745 ä. Successful treatment of plasma exchange followed by intravenous immunogloblin in a critically ill patient with 2019 novel coronavirus infection
32226289 2020. Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2
32218340 2020. Could Intravenous Immunoglobulin Collected from Recovered Coronavirus Patients Protect against COVID-19 and Strengthen the Immune System of New Patients?
32254064 2020. Deployment of convalescent plasma for the prevention and treatment of COVID-19
32305026 ä. Challenges of Convalescent Plasma Therapy on COVID-19
32167489 ä. The convalescent sera option for containing COVID-19
32348485 ä. Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in COVID-19 Patients
| 32249185 ä. Duration of serum neutralizing antibodies for SARS-CoV-2: Lessons from SARS-CoV infection |
32281317 2020. Use of Convalescent Plasma Therapy in Two COVID-19 Patients with Acute Respiratory Distress Syndrome in Korea
32219428 2020. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma
32313872 ä. COVID-19 convalescent plasma transfusion
